← Leaderboards
Sarah Cooley
University Of Minnesota
$93,263
Attributed
$93,263
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $66.9K · FY2007–09$100K$75K$50K$25K$0
'07
'08
'09
Funding mix
By agency
NIH$93,263 · 9
By mechanism
M01$93,263 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota
Same institution · by research overlap
- Bruce R. Blazar$144,460,093
- Jeffrey S Miller$32,066,338
- Douglas Yee$35,505,227
- John E Wagner$7,593,142
- Carol Ann Lange$17,870,830
Others in their field
Top investigators on “Source”
- Richard A Gibbs · Baylor College Of Medicine$285,393,445
- David Heimbrook · Leidos Biomedical Research, Inc.$233,184,481
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Jeffrey P Krischer · University Of South Florida$224,745,020
- Albert Lazzarini · California Institute Of Technology$202,317,285
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$155,571,437
Research focus
SourceUnited States National Institutes Of HealthResourcesFundingGrantInstitutionResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseSafetyDoseLaboratory StudyImmuneClinical EfficacyToxic EffectNatural Killer CellsInjections, SubcutaneousClinical Trials, Phase IiCancer TherapyDisease RemissionAllogenicProtocols, TreatmentFludarabineExcisionEnvironment
Grant awards (9)
MT2006-02: PHASE II STUDY OF 852A ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH M$1,463
M01 · FY2009 · RR · contact PI
MT2005-08-ALLOGENEIC NATURAL KILLER CELLS IN PATIENTS WITH ADVANCED METASTATIC B$732
M01 · FY2009 · RR · contact PI
MT2006-02: PHASE II STUDY OF 852A ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH M$38,429
M01 · FY2008 · RR · contact PI
MT2003-23:NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RI$24,780
M01 · FY2008 · RR · contact PI
MT2005-08-ALLOGENEIC NATURAL KILLER CELLS IN PATIENTS WITH ADVANCED METASTATIC B$2,849
M01 · FY2008 · RR · contact PI
MT2005-20: PHASE II STUDY OF 852A ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH H$884
M01 · FY2008 · RR · contact PI
MT2006-02: PHASE II STUDY OF 852A ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH M$16,084
M01 · FY2007 · RR · contact PI
MT2005-08-ALLOGENEIC NATURAL KILLER CELLS IN PATIENTS WITH ADVANCED METASTATIC B$5,798
M01 · FY2007 · RR · contact PI
MT2005-20: PHASE II STUDY OF 852A ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH H$2,244
M01 · FY2007 · RR · contact PI